CTMX Stock Summary and Trading Ideas (Cytomx Therapeutics | NASDAQ:CTMX)

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Cytomx Therapeutics trades on the NASDAQ stock market under the symbol CTMX.

As of March 3, 2025, CTMX stock price declined to $0.65 with 247,461 million shares trading.

CTMX has a beta of 2.13, meaning it tends to be more sensitive to market movements. CTMX has a correlation of 0.03 to the broad based SPY ETF.

CTMX has a market cap of $50.87 million. This is considered a Micro Cap stock.

Last quarter Cytomx Therapeutics reported $33 million in Revenue and $.07 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.24.

In the last 3 years, CTMX traded as high as $5.85 and as low as $.65.

The top ETF exchange traded funds that CTMX belongs to (by Net Assets): VTI, VXF, FORH, FESM, IWC.

CTMX has underperformed the market in the last year with a price return of -74.4% while the SPY ETF gained +17.7%. CTMX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.3% and -18.4%, respectively, while the SPY returned -1.3% and -3.4%, respectively.

CTMX support price is $.64 and resistance is $.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTMX shares will trade within this expected range on the day.